Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-10-01
Mahon Paul A Files United Therapeutics (UTHR) Form 4 - October 01, 2026
Mahon Paul A traded 16.6K UTHR shares worth $5.9M in this Form 4 filing, reported to the SEC on 2026-10-01.
- Insider
- Mahon Paul A
- Issuer
- United Therapeutics Corp. UTHR · NASDAQ
- Filed
- Period
- 2026-10-01
- Accession
- 0001231589-26-000021
- Source
- Official filing on sec.gov ↗
Transactions (12)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Mahon Paul A | 2026-10-01 | Buy | 8.3K | $146.03 | $1.2M | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 880 | $558.30 | $491.3K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 1.5K | $560.19 | $829.1K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 780 | $561.87 | $438.3K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 1.5K | $563.09 | $833.4K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 400 | $566.41 | $226.6K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 720 | $567.76 | $408.8K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 739 | $569.15 | $420.6K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 838 | $570.90 | $478.4K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 823 | $572.25 | $471.0K | Direct |
| Mahon Paul A | 2026-10-01 | Sell | 160 | $573.15 | $91.7K | Direct |
| Net change | 0 | −$3.5M | ||||
About United Therapeutics Corp.
United Therapeutics Corp. is a biotechnology company focused on developing and commercializing medicines for patients with serious, chronic, and life-threatening diseases. Its portfolio centers on therapies for pulmonary arterial hypertension, including inhaled, oral, and injectable treatments built around treprostinil, as well as additional products for selected rare and severe conditions. The company also markets delivery systems and related treatment options that support ongoing care in specialized respiratory and cardiovascular settings. United Therapeutics Corp. serves patients, clinicians, and healthcare providers across the United States and international markets, with a business model centered on specialty pharmaceuticals and disease-specific therapies. Headquartered in Silver Spring, Maryland, United Therapeutics Corp. operates as a biotechnology company with a strong focus on addressing complex unmet medical needs through commercial products and targeted treatment platforms.
Track UTHR insider activity
Get alerted when United Therapeutics Corp. executives buy or sell their shares.